Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD38 | P28907 | 12/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.43 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30142564 | 1.00 | CD38 (1.00) | CD38ADORA2BADORA2AKLKB1 | |
| SCHEMBL29494891 | 0.85 | CD38 (1.00) | CD38ADORA2AKLKB1 | |
| SCHEMBL22932675 | 0.85 | CD38 (1.00) | CD38ADORA2AKLKB1 | |
| SCHEMBL22946861 | 0.78 | CD38 (1.00) | CD38ADORA2BADORA2A | |
| SCHEMBL29696387 | 0.78 | CD38 (1.00) | CD38ADORA2BADORA2A | |
| SCHEMBL22933159 | 0.76 | CD38 (0.70) | CD38KLKB1 | |
| SCHEMBL29696520 | 0.76 | CD38 (0.70) | CD38KLKB1 | |
| SCHEMBL31484638 | 0.74 | CD38 (0.58) | CD38 | |
| SCHEMBL31484487 | 0.71 | CD38 (1.00) | CD38KLKB1 | |
| SCHEMBL22932801 | 0.71 | CD38 (1.00) | CD38KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312586-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-10-05 | — | — | US | disclosed |
| US-20230312586-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-10-05 | — | — | US | disclosed |
| US-11535621-B2 | Heterobicyclic amides as inhibitors of CD38 | RIBON THERAPEUTICS, INC. (US) | 2022-12-27 | — | — | US | disclosed |
| US-20210032251-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210032251-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | CD38, PARP12, ENTPD2 | CD38 1/4885ADORA2B 972/4885ADORA2A 671/4885 |
| US-20230312586-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | CD38, PARP12, ENTPD2 | CD38 1/4885ADORA2B 972/4885ADORA2A 671/4885 |
| US-11535621-B2 | Heterobicyclic amides as inhibitors of CD38 | CD38, PARP12, ENTPD2 | CD38 1/4885ADORA2B 972/4885ADORA2A 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.